RCEL — AVITA Medical, Inc.

Summary of AVITA Medical, Inc. Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 Revenue: $17.6 million, a decrease from $18.4 million in Q4 2024.
• Full Year Revenue: Approximately $71.6 million, representing an 11% growth over 2024.
• Gross Margin: Q4 gross margin was 81.2%, down from 87.6% in the prior year, attributed to inventory reserves and product mix.
• Operating Expenses: Q4 operating expenses were $24.7 million, down 5% year-over-year, primarily due to reduced sales and marketing costs. Excluding one-time severance costs of $1.2 million, operating expenses declined by 10%.
• Cash Position: Ended Q4 with $18.2 million in cash and marketable securities. Net cash use improved to $5.1 million in Q4, down from $10.1 million in Q2.

2. Strategic Updates and Business Highlights

• Focused on disciplined execution and refining commercial strategies, particularly in core burn and trauma centers.
• Resolved reimbursement uncertainties for ReCell, with six of seven Medicare Administrative Contractors (MACs) publishing payment rates, enhancing clinician confidence.
• Shifted sales strategy from bulk ordering to organic monthly usage patterns, emphasizing increased adoption and utilization of products.
• Continued development of clinical evidence for the multiproduct platform, with ongoing studies for CoHiliX and PermeDerm expected to yield data in 2026.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected to be between $80 million and $85 million, representing a growth of 12% to 19% over 2025.
• Growth is anticipated from normalized ReCell utilization, expanded use of CoHiliX and PermeDerm, and a more predictable operating environment.

4. Bad News, Challenges, or Points of Concern

• Q4 revenue decline compared to the previous year raises concerns about immediate growth momentum.
• Gross margin contraction due to product mix and inventory reserves could impact profitability.
• The seventh MAC has not yet published payment rates, creating uncertainty, although management is optimistic about resolution.
• Ongoing administrative bottlenecks in the VAC process for CoHiliX may delay growth, although no significant denials have been reported.

5. Notable Q&A Insights

• Management clarified that the $15.4 million revenue covenant is not indicative of Q1 guidance, emphasizing that they expect to exceed this figure.
• The company is seeing early signs of improved utilization as reimbursement clarity is restored, with a focus on increasing adoption within existing accounts.
• Questions about CoHiliX and PermeDerm adoption indicate a strong potential for cross-utilization with ReCell, although the full impact on growth remains to be seen.
• Management noted that while there are no significant bottlenecks in the VAC process, the timeline for approvals varies by account, which could affect the pace of growth.

Overall, AVITA Medical is positioning itself for growth in 2026 through improved operational execution and strategic focus, despite facing challenges in revenue and margin performance.